Phase 1 N=24 PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion
Fabry Disease
Primary: Maximum Serum Concentration of Agalsidase Beta (Cmax) — 95.51; 109.65 mU/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 5; 3; 5; 6 Participants
N/A N=1,170 A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination
Cervical Cancer · Anal Cancer · Penile Cancer
Primary: Attitudes — 5.61; 5.56; 5.51 score on a scale
N/A N=50 Improving Outcomes for Older Veterans With Chronic Back Pain and Depression
Chronic Back Pain · Depression · Aging
Primary: Rate of Intervention Completion — 22; 15 Participants
Phase 4 N=12 The Influence of Capsaicin Gel During Exercise Within the Heat
Acute Exercise · Heat Exposure
Primary: Skin Blood Flow — 188.4; 139.2 arbitrary units — p=0.284
N/A N=5,194 Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
Inflammatory Bowel Diseases · Colitis, Ulcerative · Crohn Disease
Primary: TDM Cohort: Correlation Between Week 6 Vedolizumab TDM and Week 30 Faecal Calprotectin (FCP) — -0.23 correlation coefficient — p==0.003
N/A N=20 Internal Jugular Vein Compression Collar for Novel Symptomatic Treatment of Venous Pulsatile Tinnitus
Pulsatile Tinnitus
Primary: Change From Baseline in Pulsatile Tinnitus Symptom Intensity — 3 units on a scale — p=<0.0001
N/A N=42 Integrated Supported Biopsychosocial Self-Management for Back Related Leg Pain
Low Back Pain · Sciatica · Back Related Leg Pain
Primary: Number of Particpants Screened Per Month — 103 participants per month
Phase 1 N=200 A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection
Healthy
Primary: Area Under the Concentration-time Curve of BI 695501 in Plasma Over the Time Interval From 0 to 1344 Hours After Dose Administration (AUC0-1344) — 1415.103; 1389.021…
N/A N=463 Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Pulmonary Disease, Chronic Obstructive
Primary: Change in Modified Medical Research Council (mMRC) Score Between Baseline and After End of Observation — 0.23; 0.25 Change in score on a scale
Phase 2 N=114 Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
Alzheimer Disease
Primary: Annualized Rate of Change in Tau Burden — 0.0124; 0.0254 SUVR per year — p=0.1953
N/A N=42 Laryngeal Vibration for Spasmodic Dysphonia
Spasmodic Dysphonia
Primary: Voice Assessment During First Visit — 0.045; 0.17; 0.13; -0.47 decibel
Phase 2 N=156 SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
Nasopharyngeal Carcinoma
Primary: Objective Response Rate (ORR) Assess by Independent Review Committee (IRC) — 28.3 percentage of participants
Phase 3 N=1,803 Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Breast Cancer
Primary: Comparison of Anastrozole vs Tamoxifen in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Disease-free Survival (DFS) — NA; NA; NA; NA years…
Phase 2 N=220 A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
Hepatocellular Carcinoma Non-Resectable
Primary: Objective Response Rate — 11.9; 16.7 percentage of participants